Literature DB >> 29102244

An UHPLC-MS/MS method for simultaneous quantification of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid using micro-elution solid phase extraction.

Ping-Ping Lin1, Wei-Li Chen1, Fei Yuan1, Lei Sheng1, Yu-Jia Wu2, Wei-Wei Zhang3, Guo-Qing Li3, Hong-Rong Xu4, Xue-Ning Li5.   

Abstract

Amyloid beta (Aβ) peptides in cerebrospinal fluid are extensively estimated for identification of Alzheimer's disease (AD) as diagnostic biomarkers. Unfortunately, their pervasive application is hampered by interference from Aβ propensity of self-aggregation, nonspecifically bind to surfaces and matrix proteins, and by lack of quantitive standardization. Here we report on an alternative Ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for simultaneous measurement of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid (CSF) using micro-elution solid phase extraction (SPE). Samples were pre-processing by the mixed-mode micro-elution solid phase extraction and quantification was performed in the positive ion multiple reaction monitoring (MRM) mode using electrospray ionization. The stable-isotope labeled Aβ peptides 15N51- Aβ1-38, 15N53- Aβ1-40 and 15N55- Aβ1-42 peptides were used as internal standards. And the artificial cerebrospinal fluid (ACSF) containing 5% rat plasma was used as a surrogate matrix for calibration curves. The quality control (QC) samples at 0.25, 2 and 15ng/mL were prepared. A "linear" regression (1/x2 weighting): y=ax+b was used to fit the calibration curves over the concentration range of 0.1-20ng/mL for all three peptides. Coefficient of variation (CV) of intra-batch and inter-batch assays were all less than 6.44% for Aβ1-38, 6.75% for Aβ1-40 and 10.74% for Aβ1-42. The precision values for all QC samples of three analytes met the acceptance criteria. Extract recoveries of Aβ1-38, Aβ1-40 and Aβ1-42 were all greater than 70.78%, both in low and high QC samples. The stability assessments showed that QC samples at both low and high levels could be stable for at least 24h at 4°C, 4h at room temperature and through three freeze-thaw cycles without sacrificing accuracy or precision. And no significant carryover effect was observed. This validated UHPLC/MS/MS method was successfully applied to the quantitation of Aβ peptides in real human CSF samples. Our work may provide a reference method for simultaneous quantitation of human Aβ1-38, Aβ1-40 and Aβ1-42 from CSF.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid β Peptide; Human cerebrospinal fluid; Simultaneous quantification; UHPLC–MS/MS

Mesh:

Substances:

Year:  2017        PMID: 29102244     DOI: 10.1016/j.jchromb.2017.10.047

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Comparative studies for amyloid beta degradation: "Neprilysin vs insulysin", "monomeric vs aggregate", and "whole Aβ40 vs its peptide fragments".

Authors:  Dai Kato; Yoshiaki Takahashi; Haruto Iwata; Yusuke Hatakawa; Seon Hwa Lee; Tomoyuki Oe
Journal:  Biochem Biophys Rep       Date:  2022-05-09

2.  An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid-β 1-40 and 1-42 peptides in CSF.

Authors:  Mari L DeMarco; Quyen Nguyen; Alice Fok; Ging-Yuek Robin Hsiung; J Grace van der Gugten
Journal:  Alzheimers Dement (Amst)       Date:  2020-06-30

3.  Identification of a noncoding RNA‑mediated gene pair‑based regulatory module in Alzheimer's disease.

Authors:  Lin Yu; Shi Qian; Sun Wei
Journal:  Mol Med Rep       Date:  2018-06-19       Impact factor: 2.952

4.  Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry.

Authors:  Yusuke Seino; Takumi Nakamura; Tomoo Harada; Naoko Nakahata; Takeshi Kawarabayashi; Tetsuya Ueda; Masamitsu Takatama; Mikio Shoji
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 5.  Proteomics Landscape of Alzheimer's Disease.

Authors:  Ankit P Jain; Gajanan Sathe
Journal:  Proteomes       Date:  2021-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.